{"nct_id":"NCT01696045","title":"Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma","status":"TERMINATED","status_verified_date":"2017-07","start_date":"2012-11-12","start_date_type":"ACTUAL","primary_completion_date":"2016-07-31","primary_completion_date_type":"ACTUAL","completion_date":"2016-07-31","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["BMY"]}